Welcome to Fasteris

A Swiss biotechnology company based in Geneva.

Dear valued customers,

As your trusted partner, we value your well-being and understand that the scientific community is also impacted by the novel coronavirus (COVID-19) disease. We are committed to providing consistent and timely support that your important work will not be interrupted.

Fasteris is carefully applying the safety instructions of the Swiss authorities and will be responding quickly as the situation evolves. We already have implemented the following measures:

  • Safety pre-cautions for our collaborators and all visitors
  • Re-organization of our production to be ready for possible staff reduction
  • Prepare ourselves for increased demand for some analyses
  • Ensuring to be available for communication via e-mail, telephone and/or video, as usual

However, we cannot exclude that some projects turn-around time (TAT) may be impacted and we will do our best to ensure that results are provided as quickly as possible. Since research is playing a key role to understand and minimize the impact of the coronavirus outbreak, we are doing our best to support these projects and collaborate with various institutions.

In parallel, in collaboration with our Medisupport and Sonic Healthcare colleagues, we are also reviewing our medical analyses production pipelines to ensure being able to deliver the expected results to patients and doctors.

Please do not hesitate to contact us in case of question. Thank you for your important work, and please take care of yourselves.

Yours sincerely,

Your Fasteris Service Teams

 

We are provider of Next-Generation Sequencing & Sanger DNA sequencing services. We work worldwide for private, academic and industrial research laboratories. Since 2012, we provide NGS services for medical diagnostics.

Medical diagnostics

  • Fasteris provides NGS services for medical genetics tests performed in collaboration with Medisupport laboratories.
  • In 2017, Fasteris has obtained ISO 15189 accreditation for the NGS part of Prendia, the non-invasive prenatal test (NIPT) developed with Medisupport laboratories and SIB. We also obtained federal authorizations for medical genetics, including the specific authorization of preimplantation genetic screening (PGS).

Next-Generation Sequencing (NGS) for researchers

  • Our founders are inventors of the "cluster technology" (PAT 1996) and of Y-shape adaptors - technology that meanwhile is commonly used in illumina sequencing systems.
  • Starting in 2007, FASTERIS has developed a very broad range of applications for the analysis of genomes, transcriptomes or metagenomes. We cover all steps from "library preparation" to "bioinformatics analysis".
  • In 2017 and again in 2019, we have been awared "illumina Propel Certified".
  • In 2018, we were certified to "ISO9001:2015".
  • In 2019, we have upgraded our machinery equipment with illumina NovaSeq 6000.

Our most popular products and library services

Customised services

  • Our experts are happy to assist researchers in developing custom protocols.
  • All the protocols can be performed with multiplexing of several samples per lane to reduce the overall sequencing costs.
  • We offer the flexibility to prepare libraries according to your needs.
  • We will provide you with the highest quality sequences from large or small numbers of samples by using the latest NGS technology.
  • Our machines are upgraded to latest technology or latest available chemistry version.

Bioinformatics

  • Whether your samples were sequenced at Fasteris or elsewhere, our experienced bioinformaticians will help you extract the biologically meaningful information from the billions of bases of your NGS data.

Sanger Sequencing

  • Our professionals are dedicated to offer the highest quality Sanger (Capillary) DNA Sequencing: they will provide you with personalized advice and deliver results within 24 hours.

Research & Development

  • Experienced scientists at your service to develop custom protocols for the success of your projects.

 

Last update 2020/03/13